Unichem Lab Reports Q1 Net Loss of 10.47 Crore, Revenue Rises to 526.60 Crore Aug 04, 2025
More news about Unichem Laboratories
23Jun 25
Unichem Labs' Roha API Facility Receives Three Form 483 Observations from USFDA
Unichem Laboratories Ltd's Active Pharmaceutical Ingredient (API) facility in Roha underwent a USFDA inspection, resulting in three Form 483 observations. Form 483 indicates potential violations of the Food Drug and Cosmetic Act. The company is expected to analyze the observations, develop a corrective action plan, implement changes, and respond formally to the USFDA. The outcome of this process could impact Unichem's regulatory standing and facility operations.
28Mar 25
Unichem Laboratories to Close UK Manufacturing Facility and Divest Irish Subsidiary
Unichem Laboratories is transferring its 100% stake in Unichem Ireland to IPCA Laboratories for ₹4.00 crore, expected to complete by April 30, 2025. The company is also closing its UK manufacturing facility. Additionally, Unichem is shutting down its wholly-owned subsidiary Niche Generics Limited's facility in Ireland due to continuous losses, aging infrastructure, and lease expiration. Unichem plans to manufacture the affected products at its Indian facilities for better economies of scale.
21Mar 25
Unichem Laboratories Completes Phase I API Plant Expansion, Boosts Capacity by 210 KL
Unichem Laboratories has completed Phase I expansion of its API plant in Pithampur, adding 210 KL capacity at an investment of Rs 200 crore. The expansion increases the plant's total API capacity by 81% to 469.50 KL. Financed through internal accruals and bank borrowings, the expanded capacity will primarily serve the company's internal requirements. This strategic move aims to enhance Unichem's self-reliance in API supply and potentially improve its supply chain control and production costs.
20Mar 25
Unichem Laboratories Boosts API Capacity with ₹200 Crore Expansion at Pithampur Plant
Unichem Laboratories has completed the first phase of expansion at its API plant in Pithampur, investing ₹200 crore to add 210 KL of capacity. This nearly doubles the facility's capacity from 259.50 KL to 469.50 KL. The expansion, funded through internal accruals and bank borrowings, aims to serve internal requirements and potentially capture a larger market share in the API segment. The existing capacity utilization was around 70% before the expansion.
02Mar 25
Unichem Laboratories' Pithampur API Facility Inspection Concludes; Company Announces Sale of Mumbai Property
Unichem Laboratories underwent a USFDA inspection at its Pithampur API facility, resulting in four procedural observations. The company will respond within 15 days. Separately, Unichem's Board approved the sale of a 3.40-acre Mumbai property to Macrotech Developers for ₹279 crores, with completion expected by June 30, 2025. The property's book value is ₹2.18 crores, indicating a significant gain from the sale.
02Mar 25
Unichem Laboratories to Sell Jogeshwari Property for Rs 279 Crore
Unichem Laboratories has approved the sale of a 3.40-acre property in Mumbai to Macrotech Developers Limited for Rs 279 crore. The property, previously the company's registered office, has a book value of Rs 2.18 crore. The transaction is expected to complete by June 30, 2025, and will not impact ongoing business operations. This move is part of Unichem's strategy to monetize non-core assets and focus on its pharmaceutical activities.